Virtual screening and scaffold hopping based on GRID molecular interaction fields

Journal of Chemical Information and Modeling

Volumn 45, Issue 5, 2005, Pages 1313-1323

  Ahlström, Marie M ^a,b   Ridderström, Marianne ^a   Luthman, Kristina ^b   Zamora, Ismael ^c,d  

^a ASTRAZENECA R AND D   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c SL   (Spain)

^d UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD; COMBINATORIAL MATHEMATICS; COMPLEXATION; CONFORMATIONS; DATABASE SYSTEMS; MOLECULAR DYNAMICS;

BLOOD COAGULATION; CORE STRUCTURES; MOLECULAR INTERACTION FIELDS (MIF); THROMBIN;

VIRTUAL REALITY;

THROMBIN;

ARTICLE; BINDING SITE; BIOLOGY; CHEMICAL STRUCTURE; CHEMISTRY; COMPUTER PROGRAM; DRUG ANTAGONISM; DRUG DESIGN; METABOLISM; METHODOLOGY; PROTEIN BINDING; PROTEIN CONFORMATION; X RAY CRYSTALLOGRAPHY;

BINDING SITES; COMPUTATIONAL BIOLOGY; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN CONFORMATION; SOFTWARE; THROMBIN;

EID: 26944441280     PISSN: 15499596     EISSN: 1549960X     Source Type: Journal    
DOI: 10.1021/ci049626p     Document Type: Article

References (63)

1. Willett, P. Chemical Similarity Searching. J. Chem. Inf. Comput. Sci. 1998, 38, 983-996.
2. Frimurer, T. M.; Bywater, R.; Naerum, L.; Lauritsen, L. N.; Brunak, S. Improving the odds in discriminating "drug-like" from "non drug-like" compounds. J. Chem. Inf. Comput. Sci. 2000, 40, 1315-1324.
3. Schneider, G.; Neidhart, W.; Giller, T.; Schmid, G. "Scaffold- Hopping" by Topological Pharmacophore Search: A Contribution to Virtual Screening. Angew. Chem., Int. Ed. 1999, 38, 2894-2896.
4. Sadowski, J.; Kubinyi, H. A scoring scheme for discriminating between drugs and nondrugs. J. Med. Chem. 1998, 41, 3325-3329.
5. Forino, M.; Jung, D.; Easton, J. B.; Houghton, P. J.; Pellecchia, M. Virtual docking approaches to protein kinase B inhibition. J. Med. Chem. 2005, 48, 2278-2281.
6. Evers, A.; Klabunde, T. Structure-based drug discovery using GPCR homology modeling: successful virtual screening for antagonists of the alpha1A adrenergic receptor. J. Med. Chem. 2005, 48, 1088-1097.
7. Mozziconacci, J. C.; Arnoult, E.; Bernard, P.; Do, Q. T.; Marot, C. Optimization and validation of a docking-scoring protocol; application to virtual screening for COX-2 inhibitors. J. Med. Chem. 2005, 48, 1055-1068.
8. Christmann-Franck, S.; Bertrand, H. O.; Goupil-Lamy, A.; der Garabedian, P. A.; Mauffret, O. Structure-based virtual screening: an application to human topoisomerase II alpha. J. Med. Chem. 2004, 47, 6840-6853.
9. Krovat, E. M.; Fruhwirth, K. H.; Langer, T. Pharmacophore identification, in silico screening, and virtual library design for inhibitors of the human factor Xa. J. Chem. Inf. Model. 2005, 45, 146-159.
10. Martin, Y. C. 3D database searching in drug design. J. Med. Chem. 1992, 35, 2145-2154.
11. Bender, A.; Mussa, H. Y.; Gill, G. S.; Glen, R. C. Molecular surface point environments for virtual screening and the elucidation of binding patterns (MOLPRINT 3D). J. Med. Chem. 2004, 47, 6569-6583.
12. Honma, T.; Hayashi, K.; Aoyama, T.; Hashimoto, N.; Machida, T. Structure-based generation of a new class of potent Cdk4 inhibitors: new de novo design strategy and library design. J. Med. Chem. 2001, 44, 4615-4627.
13. Naerum, L.; Norskov-Lauritsen, L.; Olesen, P. H. Scaffold hopping and optimization towards libraries of glycogen synthase kinase-3 inhibitors. Bioorg. Med. Chem. Lett. 2002, 12, 1525-1528.
14. Schmidt, J. M.; Mercure, J.; Tremblay, G. B.; Page, M.; Kalbakji, A. De novo design, synthesis, and evaluation of novel nonsteroidal phenanthrene ligands for the estrogen receptor. J. Med. Chem. 2003, 46, 1408-1418.
15. Lloyd, D. G.; Buenemann, C. L.; Todorov, N. P.; Manallack, D. T.; Dean, P. M. Scaffold hopping in de novo design. Ligand generation in the absence of receptor information. J. Med. Chem. 2004, 47, 493-496.
16. Lewell, X. Q.; Jones, A. C.; Bruce, C. L.; Harper, G.; Jones, M. M. Drug rings database with web interface. A tool for identifying alternative chemical rings in lead discovery programs. J. Med. Chem. 2003, 46, 3257-3274.
17. Jenkins, J. L.; Glick, M.; Davies, J. W. A 3D Similarity Method for Scaffold Hopping from Known Drugs or Natural Ligands to New Chemotypes. J. Med. Chem. 2004, 47, 6144-6159.
18. Cramer, R. D.; Jilek, R. J.; Guessregen, S.; Clark, S. J.; Wendt, B. "Lead hopping". Validation of topomer similarity as a superior predictor of similar biological activities. J. Med. Chem. 2004, 47, 6777-6791.
19. Rush, I. T.; Grant, J. A.; Mosyak, L.; Nicholls, A. A shape-based 3-D scaffold hopping method and its application to a bacterial protein-protein interaction. J. Med. Chem. 2005, 48, 1489-1495.
20. Bohm, M.; St. Rzebecher, J.; Klebe, G. Three-dimensional quantitative structure-activity relationship analyses using comparative molecular field analysis and comparative molecular similarity indices analysis to elucidate selectivity differences of inhibitors binding to trypsin, thrombin, and factor Xa. J. Med. Chem. 1999, 42, 458-477.
21. Bone, R.; Lu, T.; Illig, C. R.; Soll, R. M.; Spurlino, J. C. Structural analysis of thrombin complexed with potent inhibitors incorporating a phenyl group as a peptide mimetic and aminopyridines as guanidine substitutes. J. Med. Chem. 1998, 41, 2068-2075.
22. Burgey, C. S.; Robinson, K. A.; Lyle, T. A.; Sanderson, P. E.; Lewis, S. D. Metabolism-directed optimization of 3-aminopyrazinone acetamide thrombin inhibitors. Development of an orally bioavailable series containing PI and P3 pyridines. J. Med. Chem. 2003, 46, 461-473.
23. Carroll, A. R.; Pierens, G. K.; Fechner, G.; De Almeida Leone, P.; Ngo, A. Dysinosin A: a novel inhibitor of Factor VIIa and thrombin from a new genus and species of Australian sponge of the family Dysideidae. J. Am. Chem. Soc. 2002, 124, 13340-13341.
24. Hauel, N. H.; Nar, H.; Priepke, H.; Ries, U.; Stassen, J. M. Structure-based design of novel potent nonpeptide thrombin inhibitors. J. Med. Chem. 2002, 45, 1757-1766.
25. Jhoti, H.; Cleasby, A.; Reid, S.; Thomas, P. J.; Weir, M. Crystal structures of thrombin complexed to a novel series of synthetic inhibitors containing a 5,5-trans-lactone template. Biochemistry 1999, 38, 7969-7977.
26. Linusson, A.; Gottfries, J.; Olsson, T.; Ornskov, E.; Folestad, S. Statistical molecular design, parallel synthesis, and biological evaluation of a library of thrombin inhibitors. J. Med. Chem. 2001, 44, 3424-3439.
27. Narasimhan, L. S.; Rubin, J. R.; Holland, D. R.; Plummer, J. S.; Rapundalo, S. T. Structural basis of the thrombin selectivity of a ligand that contains the constrained arginine mimic (2S)-2-amino-(3S)-3-(1-carbamimidoyl- piperidin-3-yl)-propanoic acid at P1. J. Med. Chem. 2000, 43, 361-368.
28. Noteberg, D.; Branalt, J.; Kvarnstrom, I.; Linschoten, M.; Musil, D. New proline mimetics: synthesis of thrombin inhibitors incorporating cyclopentane- and cyclopentenedicarboxylic acid templates in the P2 position. Binding conformation investigated by X-ray crystallography. J. Med. Chem. 2000, 43, 1705-1713.
29. Pierce, A. C.; Jorgensen, W. L. Estimation of binding affinities for selective thrombin inhibitors via Monte Carlo simulations. J. Med. Chem. 2001, 44, 1043-1050.
30. St. Charles, R.; Matthews, J. H.; Zhang, E.; Tulinsky, A. Bound structures of novel P3-P1′ beta-strand mimetic inhibitors of thrombin. J. Med. Chem. 1999, 42, 1376-1383.
31. Supuran, C. T.; Scozzafava, A.; Briganti, F.; Clare, B. W. Protease inhibitors: synthesis and QSAR study of novel classes of nonbasic thrombin inhibitors incorporating sulfonylguanidine and O-methyl-sulfonylisourea moieties at P1. J. Med. Chem. 2000, 43, 1793-1806.
32. Zhang, H. C.; Derian, C. K.; Andrade-Gordon, P.; Hoekstra, W. J.; McComsey, D. F. Discovery and optimization of a novel series of thrombin receptor (par-1) antagonists: potent, selective peptide mimetics based on indole and indazole templates. J. Med. Chem. 2001, 44, 1021-1024.
33. Walker, C. P.; Royston, D. Thrombin generation and its inhibition: a review of the scientific basis and mechanism of action of anticoagulant therapies. Br. J. Anaesth. 2002, 88, 848-863.
34. Fenton, J. W., II; Ofosu, F. A.; Moon, D. G.; Maraganore, J. M. Thrombin structure and function: why thrombin is the primary target for antithrombotics. Blood Coagulation Fibrinolysis 1991, 2, 69-75.
35. Bode, W.; Mayr, I.; Baumann, U.; Huber, R.; Stone, S. R. The refined 1.9 A crystal structure of human alpha-thrombin: interaction with D-Phe-Pro-Arg chloromethylketone and significance of the Tyr-Pro-Pro-Trp insertion segment. EMBO J. 1989, 8, 3467-3475.
36. Chirgadze, N. Y.; Sall, D. J.; Briggs, S. L.; Clawson, D. K.; Zhang, M. The crystal structures of human alpha-thrombin complexed with active site- directed diamino benzo[b]thiophene derivatives: A binding mode for a structurally novel class of inhibitors. Protein Sci. 2000, 9, 29-36.
37. Martin, P. D.; Malkowski, M. G.; DiMaio, J.; Konishi, Y.; Ni, F. Bovine thrombin complexed with an uncleavable analog of residues 7-19 of fibrinogen A alpha: geometry of the catalytic triad and interactions of the P1′, P2′, and P3′ substrate residues. Biochemistry 1996, 35, 13030-13039.
38. Rarey, M.; Kramer, B.; Lengauer, T.; Klebe, G. A fast flexible docking method using an incremental construction algorithm. J. Mol. Biol. 1996, 267, 470-489.
39. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 1997, 267, 727-748.
40. Weininger, D. SMILES, a chemical Language and Information System. 1. Introduction to Methodology and Encoding Rules. J. Chem. Inf. Comput. Sci. 1988, 28, 31-36.
41. Pearlman, R. S.; Balducci, R. Confort: A Novel Algorithm For Conformational Analysis. National Meeting of the American Chemical Society, New Orleans, 1998.
42. Confort; Tripos Associates Inc.: St. Louis, MO. http://www.tripos.com.
43. Goodford, P. J. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J. Med. Chem. 1985, 28, 849-857.
44. Boobbyer, D. N.; Goodford, P. J.; McWhinnie, P. M.; Wade, R. C. New hydrogen-bond potentials for use in determining energetically favorable binding sites on molecules of known structure. J. Med. Chem. 1989, 32, 1083-1094.
45. Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N. The Protein Data Bank. Nucleic Acids Res. 2000, 28, 235-242.
46. Matthews, J. H.; Krishnan, R.; Costanzo, M. J.; Maryanoff, B. E.; Tulinsky, A. Crystal structures of thrombin with thiazole-containing inhibitors: probes of the SI′ binding site. Biophys. J. 1996, 71, 2830-2839.
47. De Simone, G.; Balliano, G.; Milla, P.; Gallina, C.; Giordano, C. Human alpha-thrombin inhibition by the highly selective compounds N-ethoxycarbonyl-D- Phe-Pro-alpha-azaLys p-nitrophenyl ester and N-carbobenzoxy-Pro-alpha-azaLys p-nitrophenyl ester: A kinetic, thermodynamic and X-ray crystallographic study. J. Mol. Biol. 1997, 269, 558-569.
48. Malley, M. F.; Tabernero, L.; Chang, C. Y.; Ohringer, S. L.; Roberts, D. G. M. Crystallographic determination of the structures of human alpha-thrombin complexed with BMS-186282 and BMS-189090. Protein Sci. 1996, 5, 221-228.
49. Katz, B. A.; Mackman, R.; Luong, C.; Radika, K.; Martelli, A. Structural basis for selectivity of a small molecule, S1-binding, submicromolar inhibitor of urokinase-type plasminogen activator. Chem. Biol. 2000, 7, 299-312.
50. Friedrich, R.; Steinmetzer, T.; Bode, W. Complex structure of human thrombin with N-methyl-arginine inhibitor. To be published.
51. Katz, B. A.; Elrod, K.; Luong, C.; Rice, M. J.; Mackman, R. L. A novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site. J. Mol. Biol. 2001, 307, 1451-1486.
52. Weber, P. C.; Lee, S. L.; Lewandowski, F. A.; Schadt, M. C.; Chang, C. H. Kinetic and crystallographic studies of thrombin with AC-(D)-Phe-Pro- boroArg-OH and its lysine, amidine, homolysine, and ornithine analogs. Biochemistry 1995, 34, 3750-3757.
53. Mochalkin, I.; Tulinsky, A. Structures of thrombin retro-inhibited with SEL2711 and SEL2770 as they relate to factor Xa binding. Acta Crystallogr., Sect. D 1999, 55, 785-793.
54. Pastor, M.; Cruciani, G.; McLay, I.; Pickett, S.; Clementi, S. GRid-INdependent Descriptors (GRIND): a novel class of alignment-independent three-dimensional molecular descriptors. J. Med. Chem. 2000, 43, 3233-3243.
55. Zamora, I.; Afzelius, L.; Cruciani, G. Predicting drug metabolism: a site of metabolism prediction tool applied to the cytochrome P450 2C9. J. Med. Chem. 2003, 46, 2313-2324.
56. Carbo, R.; Leyda, L.; Arnau, M. How Similar is a Molecule to Another? An electron density measure of the similarity between two compounds. Int. J. Quantum Chem. 1980, 17, 1185-1189.
57. Stahle, L.; Wold, S. Multivariate data analysis and experimental design in biomedical research. Prog. Med. Chem. 1988, 25, 291-338.
58. Leach, A. R. Molecular Modelling Principles and Applications, 2nd ed.; Longman: New Jersey, 2001; pp 497-499, 706-708.
59. Dolle, R. E. Comprehensive survey of combinatorial library synthesis: 2001. J. Comb. Chem. 2002, 4, 369-418.
60. Dolle, R. E. Comprehensive survey of combinatorial library synthesis: 2000. J. Comb. Chem. 2001, 3, 477-517.
61. GRID, version 21; Molecular Discovery Ltd.: Pinner, Middlesex, U. K. http://moldiscovery.com.
62. Halgren, T. A. Merck Molecular Force Field. I. Basis, Form, Scope, Parametrization, and Performance of MMFF94. J. Comput. Chem. 1996, 17, 490-519.
63. Kramer, B.; Rarey, M.; Lengauer, T. Evaluation of the FLEXX incremental construction algorithm for protein-ligand docking. Proteins 1999, 37, 228-241.